AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25045434 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus Megestrol Acetate (MA) - 160 mg of MA daily plus 0.5 g of metformin thrice daily
Number of subjects: 16
Study 25045434 — intervention group
Group type: COMPARATOR
Intervention: Megestrol Acetate (MA) alone - 160 mg of MA daily
Number of subjects: 16
Study 22461535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 0
Study 22461535 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study 19414708 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of novel genetic polymorphisms in the BDNF gene
Number of subjects: 536
Study 19414708 — intervention group
Group type: EXPERIMENTAL
Intervention: Association analyses of patients with MDD
Number of subjects: 536
Study 19414708 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of antidepressant response
Number of subjects: 536
Study 19414708 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 536
Study 17551299 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field irradiation (IFI)
Number of subjects: 200
Study 17551299 — intervention group
Group type: COMPARATOR
Intervention: Elective nodal irradiation (ENI)
Number of subjects: 200
Study 15451222 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg per month
Number of subjects: 318
Study 15451222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin 0.1%)
Number of subjects: 318
Study 11435719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (+PPI)
Number of subjects: 6
Study 11435719 — intervention group
Group type: COMPARATOR
Intervention: Standard liquid test meal (-PPI)
Number of subjects: 6
Study 9886730 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (daily exercise training for 3 months)
Number of subjects: 30
Study 9886730 — intervention group
Group type: COMPARATOR
Intervention: Non-training group (no exercise training)
Number of subjects: 30
Study 9886730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training and non-training groups after percutaneous balloon mitral valvuloplasty
Number of subjects: 30
Study 8022186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 347
Study 8022186 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 347
Study 2591384 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol 0.3 g I/kg
Number of subjects: 24
Study 2591384 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol 0.6 g I/kg
Number of subjects: 24
Study 2591384 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol 1.2 g I/kg
Number of subjects: 24
Study 2591384 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 24
Study 778307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (200 mg, three times daily)
Number of subjects: 29
Study 778307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg, twice daily)
Number of subjects: 29
Study 778307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 29
Study 30060080 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH) for women with BMI < 35 kg/m2
Number of subjects: 404
Study 30060080 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH) for women with BMI ≥ 35 kg/m2
Number of subjects: 404
Study 26566148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + Amiodarone
Number of subjects: 105
Study 26566148 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (Control)
Number of subjects: 105
Study 26341218 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPER algorithm for early administration of analgesic drugs
Number of subjects: 442
Study 26341218 — intervention group
Group type: COMPARATOR
Intervention: Normal process of access to pain-control drugs (Group A)
Number of subjects: 442
Study 23451769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 48
Study 23451769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 48
Study 23451769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg twice daily
Number of subjects: 48
Study 23451769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 25 mg twice daily
Number of subjects: 48
Study 23451769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg once daily
Number of subjects: 48
Study 23451769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 25 mg once daily
Number of subjects: 48
Study 23451769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23451769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 48
Study 22184801 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient combination (vitamins C and D3, folic acid, and selenium)
Number of subjects: 192
Study 18663516 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 U BoNTA
Number of subjects: 142
Study 18663516 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U BoNTA
Number of subjects: 142
Study 18663516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 16856894 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap plus acellular dermal matrix (ADM)
Number of subjects: 13
Study 16856894 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap alone
Number of subjects: 13
Study 16856894 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap plus ADM
Number of subjects: 13
Study 14999218 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 68
Study 14999218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 20578847 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day per week take-home dosing schedule
Number of subjects: 24
Study 20578847 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day per week clinic dosing schedule
Number of subjects: 24
Study 20578847 — intervention group
Group type: COMPARATOR
Intervention: Daily dosing schedule
Number of subjects: 24
Study 20578847 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day per week supervised dosing
Number of subjects: 24
Study 9252908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 0.2 mg/kg three times daily
Number of subjects: 37
Study 9252908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8296578 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (imipramine, clomipramine, desipramine)
Number of subjects: 106
Study 3520319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin during labor
Number of subjects: 160
Study 31808596 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy donor FMT
Number of subjects: 35
Study 31808596 — intervention group
Group type: COMPARATOR
Intervention: Autologous FMT
Number of subjects: 35
Study 29802215 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin prophylaxis
Number of subjects: 1020
Study 29802215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study 28369278 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV viruria (detected by qualitative PCR)
Number of subjects: 260
Study 28369278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal gonorrhea
Number of subjects: 260
Study 28369278 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal HIV log10 viral load
Number of subjects: 260
Study 25753932 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavioral treatment (CBT) for high anxiety sensitivity, delivered over eight weeks.
Number of subjects: 80
Study 25753932 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 80
Study 24184053 — intervention group
Group type: EXPERIMENTAL
Intervention: PST (periosteal stimulation therapy) once a week for 10 weeks followed by PST boosters for 6 months
Number of subjects: 190
Study 24184053 — intervention group
Group type: EXPERIMENTAL
Intervention: PST for 10 weeks followed by control PST boosters for 6 months
Number of subjects: 190
Study 24184053 — intervention group
Group type: COMPARATOR
Intervention: Control PST (periosteal needles and brief electrical stimulation of control points) once a week for 10 weeks
Number of subjects: 190
Study 21409601 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic reconstruction of gastro/duodenojejunostomy
Number of subjects: 72
Study 21409601 — intervention group
Group type: COMPARATOR
Intervention: Retrocolic reconstruction of gastro/duodenojejunostomy
Number of subjects: 72
Study 21409601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (antecolic and retrocolic)
Number of subjects: 72
Study 21409601 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DGE
Number of subjects: 72
Study 21409601 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without DGE
Number of subjects: 72
Study 21409601 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 72
Study 18787510 — intervention group
Group type: EXPERIMENTAL
Intervention: IV PTX 500 mg bolus followed by IV infusion of PTX 700 mg for two hours
Number of subjects: 32
Study 18787510 — intervention group
Group type: COMPARATOR
Intervention: Normal saline as placebo
Number of subjects: 32
Study 16532160 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic score for appendicitis applied by emergency room nurses
Number of subjects: 0
Study 16532160 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group of patients not operated for appendicitis)
Number of subjects: 0
Study 15192991 — intervention group
Group type: EXPERIMENTAL
Intervention: ROI measurement in physical therapy clinical program
Number of subjects: 0
Study 15192991 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of performance measurement model
Number of subjects: 0
Study 11265909 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive fever education program
Number of subjects: 87
Study 11265909 — intervention group
Group type: COMPARATOR
Intervention: Standard written fever pamphlet
Number of subjects: 87
Study 11265909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (interactive and written)
Number of subjects: 87
Study 9284714 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIH infusion (90‐min iv infusion of SRIH at a rate of 9 micrograms/kg.h)
Number of subjects: 29
Study 9284714 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (90‐min iv infusion of isovolumetric amounts of 0.9% saline)
Number of subjects: 29
Study 9284714 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIH infusion
Number of subjects: 29
Study 8361246 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Day Health Care (ADHC) provided directly by the VA
Number of subjects: 989
Study 8361246 — intervention group
Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 989
Study 8361246 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract ADHC programs
Number of subjects: 989
Study 3532693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated diazoxide administered intravenously (n = 28)
Number of subjects: 64
Study 3532693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine administered intramuscularly (n = 24)
Number of subjects: 64
Study 3532693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drug regimens (diazoxide and dihydralazine)
Number of subjects: 64
Study 3532693 — intervention group
Group type: COMPARATOR
Intervention: Furosemide administered intravenously (40 mg)
Number of subjects: 64
Study 29441952 — intervention group
Group type: EXPERIMENTAL
Intervention: O/V ointment with 2% silver fir bark extract
Number of subjects: 61
Study 29441952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 27646425 — intervention group
Group type: COMPARATOR
Intervention: Baseline CRP levels ≤ 3.0mg/L
Number of subjects: 4038
Study 27646425 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately/markedly elevated CRP levels (≥6.9mg/L; 24% of patients)
Number of subjects: 4038
Study 24676963 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance cognitive stimulation therapy (CST) weekly group programme for 24 weeks
Number of subjects: 236
Study 24676963 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance cognitive stimulation therapy (CST) weekly group programme for 24 weeks (subgroup taking AChEIs)
Number of subjects: 236
Study 24676963 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 236
Study 22627378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductal Injection (DI) with Serva collagenase
Number of subjects: 10
Study 22627378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductal Injection (DI) with Liberase MTF
Number of subjects: 10
Study 22627378 — intervention group
Group type: COMPARATOR
Intervention: No Ductal Injection (no DI)
Number of subjects: 10
Study 19915202 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (1.6 g/day) and DHA (1.2 g/day)
Number of subjects: 30
Study 19915202 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (2.4 ml/day)
Number of subjects: 30
Study 18076918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of epirubicin plus oral administration of Lactobacillus casei preparation (3 gm per day for 1 year)
Number of subjects: 207
Study 18076918 — intervention group
Group type: COMPARATOR
Intervention: Intravesical instillation of epirubicin (30 mg/30 ml saline twice during 1 week, plus 6 additional instillations during 3 months)
Number of subjects: 207
Study 18076918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (epirubicin and epirubicin plus Lactobacillus casei)
Number of subjects: 207
Study 11396390 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 0
Study 9691402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophilia patients
Number of subjects: 326
Study 9691402 — intervention group
Group type: COMPARATOR
Intervention: Controls (male blood donors and children)
Number of subjects: 326
Study 9691402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophilia patients below age 10
Number of subjects: 326
Study 9691402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophilia patients below age 5 treated with monoclonally purified concentrate
Number of subjects: 326
Study 9691402 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were rarely treated
Number of subjects: 326
Study 7949790 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-introduction of normal diet after caffeine withdrawal
Number of subjects: 0
Study 7949790 — intervention group
Group type: COMPARATOR
Intervention: Caffeine withdrawal
Number of subjects: 0
Study 3283624 — intervention group
Group type: EXPERIMENTAL
Intervention: MP induction treatment every 6 months
Number of subjects: 320
Study 3283624 — intervention group
Group type: COMPARATOR
Intervention: VCMP induction treatment every 6 months
Number of subjects: 320
Study 3283624 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment using the induction scheme Q 8 weeks
Number of subjects: 320
Study 3283624 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy after remission induction
Number of subjects: 320
Study 30937935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 120
Study 30937935 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin (INR: 2.0-3.0)
Number of subjects: 120
Study 28272589 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized bedside attending rounds (AR) with 5 practices: pre-rounds huddle, bedside rounds, nurse integration, real-time order entry, whiteboard updates
Number of subjects: 1200
Study 28272589 — intervention group
Group type: COMPARATOR
Intervention: Usual rounding practices
Number of subjects: 1200
Study 27252760 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA+PRP
Number of subjects: 12
Study 27252760 — intervention group
Group type: COMPARATOR
Intervention: DFDBA alone
Number of subjects: 12
Study 24601137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic protocol (blood glucose between 80‐110mg/dl)
Number of subjects: 46
Study 24601137 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic protocol (blood glucose between 180‐220mg/dl)
Number of subjects: 46
Study 21254815 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision aid
Number of subjects: 76
Study 21254815 — intervention group
Group type: COMPARATOR
Intervention: Verbal description
Number of subjects: 76
Study 19058683 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink 2/Excite DSC (etch‐and‐rinse)
Number of subjects: 48
Study 19058683 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement/Clearfil Protect Bond (antibacterial and self‐etching)
Number of subjects: 48
Study 19058683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink/Multilink Primer (self‐etching)
Number of subjects: 48
Study 19058683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink Sprint (self‐adhesive)
Number of subjects: 48
Study 16458124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 0
Study 16458124 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 12920449 — intervention group
Group type: EXPERIMENTAL
Intervention: Campto
Number of subjects: 0
Study 11194089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg) plus placebo
Number of subjects: 22000
Study 11194089 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg) plus placebo
Number of subjects: 22000
Study 11194089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Raloxifene
Number of subjects: 22000
Study 9167869 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 4
Study 9167869 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy and massage combined
Number of subjects: 4
Study 9167869 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage alone
Number of subjects: 4
Study 9167869 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 4
Study 1493840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 24
Study 1493840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 24
Study 1493840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31666136 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive ventilation mode 2 (AVM2)
Number of subjects: 20
Study 31666136 — intervention group
Group type: COMPARATOR
Intervention: Adaptive mechanical ventilation according to Otis' equation (AVM)
Number of subjects: 20
Study 31666136 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive ventilation mode 2 (AVM2) in ARDS patients
Number of subjects: 20
Study 31666136 — intervention group
Group type: COMPARATOR
Intervention: Adaptive mechanical ventilation according to Otis' equation (AVM) in ARDS patients
Number of subjects: 20
Study 30899953 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal teaching method with relevant teaching materials, applying theory to practice closely, and standardizing practice.
Number of subjects: 32
Study 30899953 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal teaching method
Number of subjects: 32
Study 30899953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no teaching materials, only observation and manipulation)
Number of subjects: 32
Study 30899953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 27060151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone therapy
Number of subjects: 469
Study 25435683 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic mobilization (Group A)
Number of subjects: 36
Study 25435683 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation (Group B)
Number of subjects: 36
Study 23249431 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Program Group - supervised, progressive walking program five days per week, for up to half an hour per day
Number of subjects: 0
Study 23249431 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Interaction Group - one-on-one stationary interpersonal interaction time with study personnel
Number of subjects: 0
Study 23249431 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group - care as usual within their long-term care unit
Number of subjects: 0
Study 20358414 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom
Number of subjects: 81
Study 20358414 — intervention group
Group type: COMPARATOR
Intervention: Control (supportive care only)
Number of subjects: 81
Study 18671197 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of Ageratina pichinchensis extract (phytopharmaceutical formulation in lacquer solution) for 6 months
Number of subjects: 96
Study 18671197 — intervention group
Group type: COMPARATOR
Intervention: Control group with 8% ciclopirox lacquer solution for 6 months
Number of subjects: 96
Study 16860051 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel, 3.5 ml, vaginally, bid, for 14 days
Number of subjects: 0
Study 16860051 — intervention group
Group type: COMPARATOR
Intervention: K-Y Jelly, 3.5 ml, vaginally, bid, for 14 days
Number of subjects: 0
Study 16860051 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel
Number of subjects: 0
Study 16860051 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel and K-Y Jelly
Number of subjects: 0
Study 12842686 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome
Number of subjects: 133
Study 12842686 — intervention group
Group type: COMPARATOR
Intervention: Amadeus microkeratome
Number of subjects: 133
Study 12842686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both microkeratomes
Number of subjects: 133
Study 11001380 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 2
Study 11001380 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 2
Study 8853755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg morning dosing
Number of subjects: 32
Study 8853755 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg evening dosing
Number of subjects: 32